Table 2.
Patient characteristics and histopathological parameters of the tumors distributed into subtypes by TNBCtype-6 and PAM50 classification (n = 115)
| Parameters | TNBC (IHC) |
TNBC molecular subtypes |
PAM50 |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
| TNBC | BL1 | BL2 | IM | M | MSL | LAR | UNS | basal | nonbasal | |
| chemotherapy & subtyping (n = 115) (100%) | (n = 20) (17%) | (n = 14) (12%) | (n = 27) (24%) | (n = 15) (13%) | (n = 5) (4%) | (n = 15) (13%) | (n = 19) (17%) | (n = 100) (87%) | (n = 15) (13%) | |
| Age at diagnosis | ||||||||||
| ≤50 years | 41 (100%) | 12 (30%)a | 5 (12%) | 9 (22%) | 3 (7%) | 0 (0%) | 5 (12%) | 7 (17%) | 37 (90%) | 4 (10%) |
| >50 years | 74 (100%) | 8 (11%) | 9 (12%) | 18 (24%) | 12 (16%) | 5 (7%) | 10 (14%) | 12 (16%) | 63 (85%) | 11 (15%) |
|
| ||||||||||
| Tumor size at time of diagnosis | ||||||||||
| <2 cm | 39 (100%) | 6 (15%) | 3 (8%) | 10 (26%) | 5 (13%) | 4 (10%) | 6 (15%) | 5 (13%) | 32 (82%) | 7 (18%) |
| >2 cm | 76 (100%) | 14 (19%) | 11 (14%) | 17 (22%) | 10 (13%) | 1 (1%) | 9 (12%) | 14 (19%) | 68 (89%) | 8 (11%) |
|
| ||||||||||
| Nodal status at time of diagnosis | ||||||||||
| Negative | 58 (100%) | 12 (21%) | 6 (10%) | 16 (27%) | 9 (16%) | 5 (9%) | 6 (10%) | 4 (7%) | 50 (86%) | 8 (14%) |
| Positive | 57 (100%) | 8 (14%) | 8 (14%) | 11 (19%) | 6 (11%) | 0 (0%) | 9 (16%) | 15 (26%) | 50 (88%) | 7 (12%) |
|
| ||||||||||
| Tumor differentiation | ||||||||||
| G1, G2 | 47 (100%) | 2 (4%)b | 6 (13%) | 10 (21%) | 7 (15%) | 3 (6%) | 12 (26%)b | 7 (15%) | 36 (77%)b | 11 (23%)b |
| G3 | 68 (100%) | 18 (26%) | 8 (12%) | 17 (25%) | 8 (12%) | 2 (3%) | 3 (4%) | 12 (18%) | 64 (94%) | 4 (6%) |
|
| ||||||||||
| TILs | ||||||||||
| <10% | 31 (100%) | 5 (16%) | 2 (67%) | 1 (3%)c | 9 (29%) | 0 (0%) | 9 (29%)c | 5 (16%) | 23 (74%)c | 8 (26%)c |
| 10–60% | 60 (100%) | 11 (18%) | 12 (20%) | 10 (17%) | 6 (10%) | 5 (8%) | 5 (8%) | 11 (18%) | 54 (90%) | 6 (10%) |
| >60% | 24 (100%) | 4 (17%) | 0 (0%) | 16 (66%) | 0 (0%) | 0 (0%) | 1 (4%) | 3 (13%) | 23 (96%) | 1 (4%) |
Values are n (%). Bold indicates statistical significance. BL1, basal-like 1; BL2, basal-like 2; IHC, immunohistochemistry; IM, immunomodulatory; LAR, luminal androgen receptor; M, mesenchymal; MSL, mesenchymal stem-like; TILs, tumor-infiltrating lymphocytes; TNBC, triple-negative breast cancer; UNS, unstable.
a
Pearson's χ2 test with Yates continuity correction.
b
Fisher's exact test (cell frequency <5).
c
Pearson's χ2 test.